Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Thioguanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.48 |
| ▸ | PI4KA | P42356 | 2/20 | 0.45 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.45 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.45 |
| ▸ | XDH | P47989 | 2/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.41 |
| ▸ | HBB | P68871 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thioguanine SCHEMBL1829350 | 0.93 | PNP (0.42) | PNPPI4KAPI4K2BPI4K2API4KB | |
| Thioguanine SCHEMBL1176577 | 0.85 | PNP (0.62) | PNPPI4KAPI4K2BPI4K2API4KB | |
| Thioguanine SCHEMBL3701 | 0.85 | PNP (0.62) | PNPPI4KAPI4K2BPI4K2API4KB | |
| Thioguanine SCHEMBL11551825 | 0.85 | PNP (0.43) | PNPPI4KAPI4K2BPI4K2API4KB | |
| Thioguanine SCHEMBL27833745 | 0.83 | PNP (0.61) | PNPPI4KAPI4K2BPI4K2API4KB | |
| Thioguanine SCHEMBL28385604 | 0.83 | PNP (0.61) | PNPPI4KAPI4K2BPI4K2API4KB | |
| Thioguanine SCHEMBL27871419 | 0.83 | PNP (0.61) | PNPPI4KAPI4K2BPI4K2API4KB | |
| Thioguanine SCHEMBL28189108 | 0.83 | PNP (0.61) | PNPPI4KAPI4K2BPI4K2API4KB | |
| Thioguanine SCHEMBL28849539 | 0.81 | PNP (0.57) | PNPPI4KAPI4K2BPI4K2API4KB | |
| Thioguanine SCHEMBL15285091 | 0.78 | PNP (0.51) | PNPPI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0105404-A1 | Derivatives of steroid compounds linked to cyotoxic agents and process for their preparation | MERCK & CO. INC. (US) | 1984-04-18 | — | — | EP | claimed |
| CN-112584824-B | Nanoparticles | 新泰福托特股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-116209439-A | Substituted N- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) arylsulfonamide analogs as cereblon modulators | 圣裘德儿童研究医院有限公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-114901366-A | RAS inhibitors | 锐新医药公司 | 2022-08-12 | — | — | CN | disclosed |
| US-8460663-B2 | Stabilized liquid anti-RSV antibody formulations | MEDIMMUNE, LLC (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120321616-A1 | STABILIZED LIQUID ANTI-RSV ANTIBODY FORMULATIONS | MEDLMMUNE, LLC (US) | 2012-12-20 | — | — | US | disclosed |
| WO-2011037973-A1 | \"CLICK\" NANOPARTICLE CONJUGATES | NORTHWESTERN UNIVERSITY (US) | 2011-03-31 | — | — | WO | disclosed |
| CN-1901939-A | Treatment of Proliferative Diseases Using Antisense IAP Oligomers and Chemotherapeutic Agents | AEGERA THERAPEUTICS INC (CA) | 2007-01-24 | — | — | CN | disclosed |
| EP-1451205-A2 | ANTISENSE THERAPY USING OLIGONUCLEOTIDES THAT TARGET HUMAN KINESIN GENES FOR TREATMENT OF CANCER | CHIRON CORPORATION (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040009156-A1 | Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer | REINHARD CHRISTOPH (US) | 2004-01-15 | — | — | US | disclosed |
| WO-2003030832-A2 | ANTISENSE THERAPY USING OLIGONUCLEOTIDES THAT TARGET HUMAN KINESIN GENES FOR TREATMENT OF CANCER | CHIRON CORPORATION (US) | 2003-04-17 | — | — | WO | disclosed |